Anthropic's biology research team demonstrated that an internal Claude model orchestrated an autonomous protein engineering pipeline to design de novo minibinder proteins that bind scorpion venom neurotoxins. Experimental designs and validation data have been released publicly on Hugging Face.

Scorpion stings cause over one million clinical envenomations annually, yet antivenoms remain expensive animal-derived serum products. Anthropic tested whether Claude could autonomously design recombinant synthetic binders. Human researchers supplied only an initial prompt and four clarifications; the model retrieved crystal structures, selected binding epitopes, orchestrated twelve computational design tools, and filtered 318,000 generated backbones.
Of the 180 Claude-selected proteins synthesized and tested across two wet labs, 17 met binding criteria against individual toxins. Two candidate proteins bound the Cn2 neurotoxin with nanomolar affinity. Anthropic emphasized that candidates were not evaluated for in vivo neutralization in animals, positioning the work as a benchmark for agentic scientific design rather than a clinical therapeutic.
What it is
- Autonomous scientific pipeline. Claude queried structural databases, chained 12 computational tools, and selected 180 candidate proteins from 318,000 options.
- Wet-lab verification. Two independent laboratories synthesized and tested the designs, confirming 17 binders with nanomolar affinity against individual toxins.
- Single-toxin success. 11 out of 60 candidates targeting single toxins demonstrated active binding, matching standard human computational design success rates.
- Multi-target limits. Designs attempting to bind all five toxins simultaneously failed, illustrating present frontier limits in multi-objective protein design.
- Open data release. Anthropic published all 211 designed sequences, docking models, and assay measurements on Hugging Face.
Sources
Did this land? Leave a reaction.
Discussion
0 commentsMembers can join the discussion
Become a member to comment and reply to other members.
Become a MemberNo comments yet
Be the first to start the discussion.